Cannabis craze comes to China stocks, drawing regulator's ire

Twitter icon

Chinese companies linked to cannabis growing tumbled Thursday, as regulators put the squeeze on one of the year’s hottest trades.

Story Continues Below

Shanghai Shunho New Materials Technology Co. and Jilin Zixin Pharmaceutical Industrial Co. both slid more than 6 per cent after the Shenzhen Stock Exchange told them to warn investors about uncertainties facing their industrial cannabis projects. In written notices, the exchange also asked the companies to submit progress reports on those businesses before April 2. Neither company immediately responded to Bloomberg’s requests for comment.

Shanghai Shunho -- whose products include cardboard and filament -- had soared 378 per cent this year prior to Thursday, while Jilin Zixin rose 142 per cent, joining the euphoria that’s driven a rally in marijuana-focused stocks elsewhere in the world. Cultivation of industrial cannabis is legal in China but only for use in fiber and seeds, the China National Narcotic Control Committee says. Other uses including for medical purposes are forbidden.

Embedded Image

Chinese investors have piled into stocks with the slightest hint of a link to industrial cannabis, ignoring companies’ warnings and a government notice said to urge authorities to tighten approval of hemp-related licenses. Shunho’s issued at least six warnings in the past two months alone reminding investors of risks in hemp.

“It’s still just a concept. We’ve seen huge gains in the near term, so it’s going to be all risks going forward,” said Yu Yingdong, a vice general manager with Shenzhen Yun-Neng Fund Management Co.

Among other stocks to slide, Yunnan Yuntianhua Co. dropped by the 10 per cent limit and cigarette package printer Shantou Dongfeng Printing Co. also fell that amount after climbing nearly 60 per cent since February, when it said an affiliate was exploring industrial cannabis opportunities. Harbin Pharmaceutical Group Co. escaped with a 6.9 per cent gain after saying it has 2 per cent interest in a project linked to industrial cannabis. Dali Pharmaceutical Co. is up 20 per cent since denying it was involved in the business earlier this month.

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Article category: 
Regional Marijuana News: